JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2024, 73(4):E1-E8 | DOI: 10.36290/csf.2024.036

Rising consumption of anticoagulants in Central and Eastern European countries in the period 2007–2019

Kateřina Malá-Ládová1, Helena ©»astná Koblihová1, 2, Eva Zimčíková1, Anna Oleárová3, Ria Benko4, Maria Matuz4, Reka Viola4, Katarina Gvozdanovic5, Pero Draganic6, Irina Iaru7, Josef Malý1
1 Department of Social and Clinical Pharmacy, Pharmaceutical Faculty in Hradec Králové, Charles University, Czech Republic
2 Department of Clinical Pharmacy, Hospital Rudolfa a Stefanie, Beneąov, Czech Republic
3 Department of Clinical Pharmacology, University Hospital Bratislava - Hospital Ruľinov, Bratislava, Slovakia
4 Institute of Clinical Pharmacy, University of Szeged, Hungary
5 Department of Pharmacoepidemiology, Teaching Institute of Public Health "Dr. Andrija ©tampar", Zagreb, Croatia
6 Agency for Medicinal Products and Medical Devices, Zagreb, Croatia
7 Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Introduction and Aim: Due to the growing incidence of thromboembolic disease and atrial fibrillation, increasing trends in anticoagulants consumption can be expected. The aim of this study was to analyse the consumption of anticoagulants in the Czech Republic, Croatia, Hungary, Romania, and Slovakia between 2007 and 2019.

Methods: A retrospective analysis of anticoagulants comprising B01AA, B01AB, B01AE, B01AF and B01AX was performed using ATC/DDD methodology. The analysis was initiated in the year before the launch of the first non-vitamin K oral anticoagulant (NOAC). The consumption of each drug was assessed based on annual data and was expressed as DDD per 1,000 population per day (DDD/TID).

Results: The overall rates of anticoagulant consumption increased in all countries. Specifically, doubled in the Czech Republic, Croatia, and Slovakia, more than tripled in Hungary and more than quadrupled in Romania. Parenteral anticoagulant consumption remained stable or decreased, while the proportion of oral anticoagulants increased from an average of 61.41% in 2009 to 66.95% in 2019. The use of vitamin K antagonists declined, with the highest rate in the Czech Republic (11.16 DDD/TID in 2019). NOAC consumption showed substantial growth: from 0.002 to 8.33 DDD/TID in the Czech Republic, 0.001 to 6.73 in Croatia, 0.009 to 8.31 in Hungary, 0.0005 to 5.40 in Romania, and 0.03 to 10.77 in Slovakia. By 2019, rivaroxaban was the most commonly used NOAC in all countries, apart from Romania.

Conclusion: The study showed an overall increase in the anticoagulant consumption. However, specific characteristics of individual countries need to be further analysed to better understand the different factors influencing utilization patterns.

Keywords: drug utilization analysis, Europe, oral anticoagulation, parenteral anticoagulation

Accepted: December 6, 2024; Published: January 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malá-Ládová K, Koblihová H©, Zimčíková E, Oleárová A, Benko R, Matuz M, et al.. Rising consumption of anticoagulants in Central and Eastern European countries in the period 2007–2019. Čes. slov. farm. 2024;73(4):E1-8. doi: 10.36290/csf.2024.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 1.1.2026

    References

    1. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016 Apr 29;118(9):1340-7. Go to original source... Go to PubMed...
    2. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217-21. Go to original source... Go to PubMed...
    3. Maly J, Dvorackova S, Zimcikova E, et al. Patterns in anticoagulant utilization in the Czech Republic during 2007-2017. J Thromb Thrombolysis. 2019 Feb;47(2):305-11. Go to original source... Go to PubMed...
    4. Afzal S, Zaidi STR, Merchant HA, et al. Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting. J Thromb Thrombolysis. 2021 Aug;52(2):646-53. Go to original source... Go to PubMed...
    5. Colacci M, Tseng EK, Sacks CA, et al. Oral Anticoagulant Utilization in the United States and United Kingdom. J Gen Intern Med. 2020 Aug;35(8):2505-7. Go to original source... Go to PubMed...
    6. Troy A, Anderson TS. National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries From 2011 to 2019. JAMA Health Forum. 2021 Jul 23;2(7):e211693. Go to original source... Go to PubMed...
    7. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Aug 30:ehae176. Go to original source... Go to PubMed...
    8. Huiart L, Ferdynus C, Renoux C, et al. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open. 2018 Mar 30;8(3):e018180. Go to original source... Go to PubMed...
    9. Hanemaaijer S, Sodihardjo F, Horikx A, et al. Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands. Int J Clin Pharm. 2015 Dec;37(6):1128-35. Go to original source... Go to PubMed...
    10. Loo SY, Dell'Aniello S, Huiart L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017 Sep;83(9):2096-106. Go to original source... Go to PubMed...
    11. Protty MB, Hayes J. Dawn of the direct-acting oral anticoagulants: trends in oral anticoagulant prescribing in Wales 2009-2015. J Clin Pharm Ther. 2017 Apr;42(2):132-4. Go to original source... Go to PubMed...
    12. Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21. Go to original source... Go to PubMed...
    13. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. Am J Med. 2015 Dec;128(12):1300-5.e2. Go to original source... Go to PubMed...
    14. Weitz JI, Semchuk W, Turpie AG, et al. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther. 2015 Nov 1;37(11):2506-14.e4. Go to original source... Go to PubMed...
    15. Gong X, He Q, Yan J, et al. A drug utilization study of oral anticoagulants in five representative cities of China between 2015 and 2019. J Clin Pharm Ther. 2022 Jan;47(1):38-45. Go to original source... Go to PubMed...
    16. Elewa H, Alhaddad A, Al-Rawi S, et al. Trends in oral anticoagulant use in Qatar: a 5-year experience. J Thromb Thrombolysis. 2017 Apr;43(3):411-6. Go to original source... Go to PubMed...
    17. Guidelines for ATC classification and DDD assignment. [Internet]. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. [cited 2021 Nov 1]. Available from: https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/
    18. Linkins LA, Hu G, Warkentin TE. Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials. Res Pract Thromb Haemost. 2018 Aug 9;2(4):678-83. Go to original source... Go to PubMed...
    19. Al-Shaer MH, Ibrahim T. Safety and Efficacy of Fondaparinux in Renal Impairment. J Pharm Technol. 2015 Aug;31(4):161-6. Go to original source... Go to PubMed...
    20. Act No. 306/2016 Coll. on the scope and conditions of reimbursement of medicines, medical devices, and dietetic foods on the basis of public health insurance and on the amendment of certain laws, as amended. [Internet]. [cited 2024 Sept 23]. Available from: https://www.slov-lex.sk/pravne-predpisy/SK/ZZ/2016/306/20170401
    21. Théry C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation. 1992 Apr;85(4):1380-9. Go to original source... Go to PubMed...
    22. Veeranki SP, Xiao Z, Levorsen A, et al. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients. Am J Cardiovasc Drugs. 2021 Jul;21(4):443-52. Go to original source... Go to PubMed...
    23. Barcellona D, Vannini ML, Fenu L, et al. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost. 1998 Dec;80(6):899-902. Go to original source...
    24. Alias SM, Nair VS, Byju P, et al. A Comparative Study on the effect of Warfarin v/s Acenocoumarol in patients with Atrial fibrillation. Research J Pharm and Tech. 2021; 14(1):1-5. Go to original source...
    25. García Rodríguez LA, Cea Soriano L, de Abajo FJ, et al. Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study. Eur J Clin Pharmacol. 2022 Mar;78(3):497-504. Go to original source... Go to PubMed...
    26. Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol. 2017 Nov;73(11):1417-1425. Go to original source... Go to PubMed...
    27. Blin P, Dureau-Pournin C, Bénichou J, et al. Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS. Am J Cardiovasc Drugs. 2020 Feb;20(1):81-103. Go to original source... Go to PubMed...
    28. Patti G, Pecen L, Lucerna M, et al. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. Am J Med. 2019 Jun;132(6):749-57.e5. Go to original source... Go to PubMed...
    29. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. Go to original source... Go to PubMed...
    30. Solla Ruiz I, Villanueva Benito I, Paredes Galán E, et al. Differences between patient driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO MEMS Study. Thromb Res. 2019;179:20-7. Go to original source... Go to PubMed...
    31. Xarelto. Summary of product characteristics. [Internet]. State Institute for Drug Control. c2010. [cited 2021 Nov 3]. Available from: https://prehledy.sukl.cz/prehled_leciv.html#
    32. Eliquis. [Internet]. State Institute for Drug Control. c2010. [cited 2021 Nov 8]. Available from: https://prehledy.sukl.cz/prehled_leciv.html#
    33. Weitz JI, Semchuk W, Turpie AG, et al. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther. 2015 Nov 1;37(11):2506-14.e4. Go to original source... Go to PubMed...
    34. Bucek Psenkova M, Visnansky M, et al. Drug Policy in Slovakia. Value Health Reg Issues. 2017 Sep;13:44-9. Go to original source... Go to PubMed...
    35. Barnes GD, Burnett A, Allen A, et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2022 Aug;54(2):197-210. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.